Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass
1 other identifier
interventional
68
1 country
1
Brief Summary
Open-heart surgery requires temporarily stopping the heart and lungs and diverting the patient's blood to an outside system that takes over the function of the heart and lungs. This is possible through the use of cardiopulmonary bypass (CPB) which diverts blood, through plastic tubing, to a heart-lung machine which includes an oxygenator. The external oxygenator works as an artificial lung. This allows cardiac surgeons to operate in a field that is free of blood, while the patient's body continues to receive healthy blood. CPB is an advanced medical technology that allows for heart surgeries, such as coronary artery bypass, heart valve surgery, and procedures involving major blood vessels. It is recognized that there are many risks associated with its use, including microscopic stress exerted on blood components by the oxygenator and tubing, which can lead to irreversible damage to the blood cells. This effect can contribute to bleeding during and after surgery. This type of bleeding can be difficult to monitor and treat, especially given the limited access to point-of-care blood testing to inform clinicians on what part of the blood is failing to function properly. The investigators will use a point-of-care machine called Plateletworks to test the function of platelets during surgeries which require CPB. Platelets are an important part of blood that help stop bleeding by forming clots. At the investigators' institution two oxygenators are currently used interchangeably. These oxygenators have different properties that may impact how platelets function. This project will help determine if using a higher pressure oxygenator increases the risk of patients bleeding. Additionally, the investigators will compare the platelet data from Plateletworks to data collected from rotational thromboelastometry (ROTEM). This will yield valuable data about commonly used oxygenators and tests which can ultimately improve patient care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 6, 2022
CompletedStudy Start
First participant enrolled
October 7, 2022
CompletedFirst Posted
Study publicly available on registry
October 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2025
CompletedApril 15, 2026
April 1, 2026
3.1 years
October 6, 2022
April 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Plateletworks change in functional platelets
Change in functional platelets during cardiopulmonary bypass as measure by Plateletworks. ((Functional Platelets start - Functional Platelets end) / Functional Platelets start) \*100%.
24 hours from start of surgery (measured at the start and the end of cardiopulmonary bypass)
Plateletworks functional platelet count
Functional platelet count at the end of cardiopulmonary bypass as measured by Plateletworks.
24 hours from start of surgery (measured at the end of cardiopulmonary bypass)
Percentage of platelets which are functional at the end of cardiopulmonary bypass
Percentage of platelets which are functional at the end of cardiopulmonary bypass as measured by Plateletworks.
24 hours from start of surgery (measured at the end of cardiopulmonary bypass)
Secondary Outcomes (1)
ROTEM change in functional platelets
24 hours from start of surgery (measured at the start and the end of cardiopulmonary bypass)
Other Outcomes (1)
Change in functional platelets per unit time on cardiopulmonary bypass
24 hours from start of surgery (measured at the start and the end of cardiopulmonary bypass)
Study Arms (2)
LivaNova Inspire
ACTIVE COMPARATORA high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
Terumo
ACTIVE COMPARATORA low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
Interventions
Eligibility Criteria
You may qualify if:
- Scheduled for non emergent cardiac surgery
- Anticipated long CPB time (Multi-vessel CABG, multi-valve surgeries, or combined CABG and valve procedures)
You may not qualify if:
- Pregnancy
- Age under 18 years on the surgery date
- Weight less than 60kg
- Any known pre-existing bleeding disorder
- Inability to provide informed consent
- Pre-existing abnormal fibrinogen level (normal: 1.8-4.7g/l)
- Significant liver disease (alanine aminotransferase or aspartate aminotransferase \> 150 U/l)
- INR \> 1.4
- PTT greater than 38 (off IV heparin for 12h prior to testing)
- Direct oral anticoagulant (DOAC) use within 72h preoperatively
- Significant renal disease (eGFR \< 50)
- Emergency surgery
- Intake of anti-platelet drugs (including ticagrelor and Plavix but excluding ASA) within three days (72h) preoperatively
- Anemia (Hb \< 110)
- Deep vein thrombosis (DVT) (within 3 months prior to OR)
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- BRADEN DULONGlead
Study Sites (1)
Halifax Infirmary site, Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H3A7, Canada
Related Publications (14)
Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA); Boer C, Meesters MI, Milojevic M, Benedetto U, Bolliger D, von Heymann C, Jeppsson A, Koster A, Osnabrugge RL, Ranucci M, Ravn HB, Vonk ABA, Wahba A, Pagano D. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018 Feb;32(1):88-120. doi: 10.1053/j.jvca.2017.06.026. Epub 2017 Sep 30. No abstract available.
PMID: 29029990BACKGROUNDDespotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion. 2008 Mar;48(1 Suppl):2S-30S. doi: 10.1111/j.1537-2995.2007.01573.x. No abstract available.
PMID: 18302579BACKGROUNDHardwick RA, Hellums JD, Peterson DM, Moake JL, Olson JD. The effect of PGI2 and theophylline on the response of platelets subjected to shear stress. Blood. 1981 Oct;58(4):678-81.
PMID: 7023570BACKGROUNDKarkouti K, McCluskey SA, Callum J, Freedman J, Selby R, Timoumi T, Roy D, Rao V. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology. 2015 Mar;122(3):560-70. doi: 10.1097/ALN.0000000000000556.
PMID: 25485470BACKGROUNDKarkouti K, Callum J, Wijeysundera DN, Rao V, Crowther M, Grocott HP, Pinto R, Scales DC; TACS Investigators. Point-of-Care Hemostatic Testing in Cardiac Surgery: A Stepped-Wedge Clustered Randomized Controlled Trial. Circulation. 2016 Oct 18;134(16):1152-1162. doi: 10.1161/CIRCULATIONAHA.116.023956. Epub 2016 Sep 21.
PMID: 27654344BACKGROUNDKaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, O'Malley BA, Sesok-Pizzini DA, Shander A, Stack GE, Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AA; AABB. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015 Feb 3;162(3):205-13. doi: 10.7326/M14-1589.
PMID: 25383671BACKGROUNDKoch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006 May;81(5):1650-7. doi: 10.1016/j.athoracsur.2005.12.037.
PMID: 16631651BACKGROUNDKwapisz MM, Kent B, DiQuinzio C, LeGare JF, Garnett S, Swyer W, Whynot S, Mingo H, Scheffler M. The prophylactic use of fibrinogen concentrate in high-risk cardiac surgery. Acta Anaesthesiol Scand. 2020 May;64(5):602-612. doi: 10.1111/aas.13540. Epub 2020 Jan 17.
PMID: 31889306BACKGROUNDMaquelin KN, Berckmans RJ, Nieuwland R, Schaap MC, ten Have K, Eijsman L, Sturk A. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998 May;115(5):1160-5. doi: 10.1016/s0022-5223(98)70416-7.
PMID: 9605086BACKGROUNDTransfusion of Red Blood Cells, Fresh Frozen Plasma, or Platelets Is Associated With Mortality and Infection After Cardiac Surgery in a Dose-Dependent Manner. Anesth Analg. 2020 Feb;130(2):e32. doi: 10.1213/ANE.0000000000004528.
PMID: 31702696BACKGROUNDRanucci M, Baryshnikova E, Castelvecchio S, Pelissero G; Surgical and Clinical Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg. 2013 Aug;96(2):478-85. doi: 10.1016/j.athoracsur.2013.03.015. Epub 2013 May 11.
PMID: 23673069BACKGROUNDRaphael J, Mazer CD, Subramani S, Schroeder A, Abdalla M, Ferreira R, Roman PE, Patel N, Welsby I, Greilich PE, Harvey R, Ranucci M, Heller LB, Boer C, Wilkey A, Hill SE, Nuttall GA, Palvadi RR, Patel PA, Wilkey B, Gaitan B, Hill SS, Kwak J, Klick J, Bollen BA, Shore-Lesserson L, Abernathy J, Schwann N, Lau WT. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg. 2019 Nov;129(5):1209-1221. doi: 10.1213/ANE.0000000000004355.
PMID: 31613811BACKGROUNDStanzel RD, Henderson M. Clinical evaluation of contemporary oxygenators. Perfusion. 2016 Jan;31(1):15-25. doi: 10.1177/0267659115604709. Epub 2015 Sep 25.
PMID: 26407816BACKGROUNDWeerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg. 1998 Dec;66(6):2145-52. doi: 10.1016/s0003-4975(98)00749-8.
PMID: 9930521BACKGROUND
Study Officials
- PRINCIPAL INVESTIGATOR
Braden Dulong, MD
Nova Scotia Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Anesthesiologist
Study Record Dates
First Submitted
October 6, 2022
First Posted
October 20, 2022
Study Start
October 7, 2022
Primary Completion
October 31, 2025
Study Completion
October 31, 2025
Last Updated
April 15, 2026
Record last verified: 2026-04